In recent years, exceptional technological advances have enabled the identification and
interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading …

Breast cancer heterogeneity determines cancer progression, treatment effects, and
prognosis. However, the precise mechanism for this heterogeneity remains unknown owing …

The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …

The recent boom in microfluidics and combinatorial indexing strategies, combined with low
sequencing costs, has empowered single-cell sequencing technology. Thousands—or even …

Abstract Models that recapitulate the complexity of human tumors are urgently needed to
develop more effective cancer therapies. We report a bank of human patient-derived …

How cell-to-cell copy number alterations that underpin genomic instability in human cancers
drive genomic and phenotypic variation, and consequently the evolution of cancer, remains …

Under the selective pressure of therapy, tumours dynamically evolve multiple adaptive
mechanisms that make static interrogation of genomic alterations insufficient to guide …

Cancer represents an evolutionary process through which growing malignant populations
genetically diversify, leading to tumour progression, relapse and resistance to therapy. In …

To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones
mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the …

Patient-specific ex vivo models of human tumours that recapitulate the pathological
characteristics and complex ecology of native tumours could help determine the most …